MCID: CNJ013
MIFTS: 65

Conjunctivitis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Conjunctivitis

Summaries for Conjunctivitis

PubMed Health : 62 About conjunctivitis: Conjunctivitis, also known as pink eye, is an inflammation of the conjunctiva. The conjunctiva is a protective membrane covering the white part of the eye and the inner side of the eyelid. When people have conjunctivitis, both of their eyes are often red because the infection can spread very easily from one eye to the other. Conjunctivitis is most commonly caused by bacteria or viruses, and sometimes by an allergy. Bacterial conjunctivitis usually gets better within a week without treatment, but viral infections can last as long as four weeks. Because the virus can easily spread through contact with your fingers, it is important not to touch an infected eye with your bare hands. If you do touch your eye, be sure to wash your hands right away. It is also a good idea to use your own towels and washcloths, and not share them with other people.

MalaCards based summary : Conjunctivitis, also known as madras eye, is related to giant papillary conjunctivitis and vernal conjunctivitis, and has symptoms including bloodshot eye, conjunctival congestion and redness of eye. An important gene associated with Conjunctivitis is PLG (Plasminogen), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pheniramine and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

CDC : 3 People often call conjunctivitis "pink eye" because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Wikipedia : 74 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Related Diseases for Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis Rare Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1519)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 34.4 RNASE3 IL6 IL4 CXCL8 CCL11
2 vernal conjunctivitis 34.3 RNASE3 IL4 IGHE IFNG
3 papillary conjunctivitis 34.2 IL6 IL4 CXCL8 CCL11
4 angelucci's syndrome 33.4 IFNG CXCL8
5 blepharoconjunctivitis 33.4 RNASE3 IL4 CXCL8 CCL11
6 chronic conjunctivitis 32.7 TNF RNASE3 IL6 IL5 IL4 IL33
7 blepharitis 32.7 TNF IL6 IL4 CXCL8
8 avian influenza 32.6 TNF IL6 CXCL8
9 stevens-johnson syndrome/toxic epidermal necrolysis 32.5 IL5 IL2 IL13 IFNG
10 graves' disease 32.4 IL4 IL13 IFNG ICAM1
11 measles 32.4 TNF TLR3 IL6 IL2 IFNG
12 kawasaki disease 32.3 TNF IL6 IL4 IL10 FOXP3
13 reactive arthritis 32.3 TNF IL6 IL10 IFNG CXCL8
14 pollen allergy 32.3 RNASE3 IL5 IL13 ICAM1 FOXP3
15 muckle-wells syndrome 32.3 NLRP3 NLRC4 CXCL8
16 trichinosis 32.0 IL5 IL4 IL13 IL10
17 allergic conjunctivitis 31.9 TNF TLR3 RNASE3 IL5 IL4 IL33
18 rubella 31.6 TNF TLR3 IL6 IL5 IL4 IL2
19 haemophilus influenzae 31.4 TNF CXCL8
20 allergic rhinitis 31.4 RNASE3 IL5 IL4 IL13 IL10 IGHE
21 chlamydia 31.3 TNF IL6 IL4 IL10 IFNG CXCL8
22 trachoma 31.3 TNF IL6 IL4 IL10 FOXP3
23 urethritis 31.2 TNF IL6 CXCL8
24 keratitis, hereditary 31.1 TNF TLR3 IL6 IL10 CXCL8
25 eye disease 31.1 TNF PLG IL6 IL5 IL4 IL2
26 vernal keratoconjunctivitis 31.0 RNASE3 IL5 IL4 IL13 IGHE CCL11
27 hashimoto thyroiditis 31.0 TNF IL6 IL5 IL4 IL2 IL10
28 keratoconjunctivitis 30.8 TNF RNASE3 IL6 IL5 IL4 IL2
29 cytokine deficiency 30.8 IL5 IL13
30 dacryoadenitis 30.8 IL13 IL10 FOXP3
31 atopic keratoconjunctivitis 30.7 RNASE3 IL5 IL4 IL2 IGHE IFNG
32 keratopathy 30.7 TNF IL4 ICAM1 CXCL8
33 scleritis 30.6 TNF IL5 IL4 IFNG
34 endophthalmitis 30.6 TNF PLG IL6 ICAM1 CXCL8
35 retinal detachment 30.6 TNF IL6 IFNG CXCL8
36 cholera 30.6 TNF IL6 IL4 CXCL8
37 chlamydia pneumonia 30.6 TNF IL6 IL10 CXCL8
38 pharyngitis 30.6 TNF NLRP3 IL6 CXCL8
39 exanthem 30.6 TNF NLRP3 IL6 IL2 IL10 CXCL8
40 poliomyelitis 30.5 TNF IL4 IL10 IFNG ICAM1
41 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.5 IL10 IFNG FOXP3
42 bullous pemphigoid 30.5 RNASE3 IL5 IL4 IL13 IGHE CXCL8
43 central nervous system lymphoma 30.5 IL6 IL2 IL10
44 graft-versus-host disease 30.5 TNF IL6 IL2 IL10 IFNG
45 cervicitis 30.5 IL6 IL2 CXCL8
46 spondylitis 30.4 TNF IL6 IL10 IFNG
47 cellulitis 30.4 TNF RNASE3 IL6 IL5 IL10
48 encephalitis 30.4 TNF TLR3 IL6 IL10
49 neurofibromatosis, type ii 30.4 TNF IL6 CXCL8
50 compartment syndrome 30.4 TNF PLG IL6

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Blepharitis
Bronchitis Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Iron Deficiency Anemia
Osteoporosis Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:



Diseases related to Conjunctivitis

Symptoms & Phenotypes for Conjunctivitis

UMLS symptoms related to Conjunctivitis:


bloodshot eye, conjunctival congestion, redness of eye, discharge from eye

GenomeRNAi Phenotypes related to Conjunctivitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CXCL8 ICAM1 IL10 IL2 NLRP3 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CXCL8 ICAM1 IL10 IL2 NLRC4 NLRP3

MGI Mouse Phenotypes related to Conjunctivitis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.44 CCL11 FOXP3 HRH1 ICAM1 IFNG IL10
2 immune system MP:0005387 10.41 CCL11 FOXP3 HRH1 ICAM1 IFNG IL10
3 cellular MP:0005384 10.37 FOXP3 ICAM1 IFNG IL10 IL13 IL2
4 homeostasis/metabolism MP:0005376 10.37 FOXP3 HRH1 ICAM1 IFNG IL10 IL13
5 digestive/alimentary MP:0005381 10.36 FOXP3 ICAM1 IFNG IL10 IL13 IL2
6 growth/size/body region MP:0005378 10.34 FOXP3 HRH1 ICAM1 IFNG IL10 IL13
7 endocrine/exocrine gland MP:0005379 10.31 FOXP3 ICAM1 IFNG IL10 IL13 IL2
8 mortality/aging MP:0010768 10.25 FOXP3 HRH1 ICAM1 IFNG IL10 IL13
9 integument MP:0010771 10.2 FOXP3 ICAM1 IFNG IL10 IL13 IL33
10 liver/biliary system MP:0005370 10.17 FOXP3 HRH1 IFNG IL10 IL2 IL4
11 nervous system MP:0003631 10.06 ICAM1 IFNG IL10 IL13 IL33 IL4
12 neoplasm MP:0002006 10.02 ICAM1 IFNG IL10 IL2 IL5 IL6
13 reproductive system MP:0005389 9.97 FOXP3 IFNG IL10 IL13 IL2 IL33
14 no phenotypic analysis MP:0003012 9.86 FOXP3 IFNG IL10 IL13 IL2 IL33
15 respiratory system MP:0005388 9.77 CCL11 FOXP3 IFNG IL10 IL13 IL2
16 vision/eye MP:0005391 9.28 FOXP3 ICAM1 IFNG IL10 IL2 IL4

Drugs & Therapeutics for Conjunctivitis

PubMed Health treatment related to Conjunctivitis: 62

Eye drops or ointments that contain antibiotics are often given as a treatment for conjunctivitis just in case it is a bacterial infection , even though conjunctivitis is more commonly caused by viruses . But antibiotics are only effective against bacteria , and have no effect on viruses. If the infection is viral, only the symptoms can be treated. Some people use non-antibiotic eye drops. Cold or warm compresses are also common. The effects of these treatments have not been properly studied, though. It is not clear if they are helpful, useless or possibly even harmful. If conjunctivitis is caused by an allergy , it can be treated with allergy medicine such as antihistamines .

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 253)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pheniramine Approved Phase 4 86-21-5 4761
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
4
Alcaftadine Approved Phase 4 147084-10-4 19371515
5
Bepotastine Approved Phase 4 190786-44-8, 125602-71-3 2350
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
11
Ofloxacin Approved Phase 4 82419-36-1 4583
12
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
13
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
14
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
15
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
16
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
17
Dipivefrin Approved Phase 4 52365-63-6 3105
18
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
19
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
20
Montelukast Approved Phase 4 158966-92-8 5281040
21
Ranibizumab Approved Phase 4 347396-82-1 459903
22
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
23
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
24
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
25
Tranilast Investigational Phase 4 53902-12-8 93543
26 Ketorolac Tromethamine Phase 4
27 Keratolytic Agents Phase 4
28 Dermatologic Agents Phase 4
29 Antipruritics Phase 4
30 Ophthalmic Solutions Phase 4
31 Immunosuppressive Agents Phase 4
32 Calcineurin Inhibitors Phase 4
33 Topoisomerase Inhibitors Phase 4
34 Anti-Bacterial Agents Phase 4
35 Antibiotics, Antitubercular Phase 4
36 HIV Protease Inhibitors Phase 4
37
protease inhibitors Phase 4
38 BB 1101 Phase 4
39 Renal Agents Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
42 Anti-Infective Agents, Urinary Phase 4
43 Platelet Aggregation Inhibitors Phase 4
44 calcium channel blockers Phase 4
45 Plasma Substitutes Phase 4
46 Anticoagulants Phase 4
47 Dextrans Phase 4
48 Blood Substitutes Phase 4
49 Polymyxins Phase 4
50 Cyclosporins Phase 4

Interventional clinical trials:

(show top 50) (show all 413)
# Name Status NCT ID Phase Drugs
1 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
2 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
3 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™) Unknown status NCT01808768 Phase 4 Alcaftadine
4 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
5 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
6 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
7 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
8 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
9 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
10 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
11 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
12 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
13 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
14 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
15 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
16 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
17 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
18 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
19 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
20 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
21 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
22 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
23 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
24 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
25 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
26 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Completed NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
27 A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis. Completed NCT00581542 Phase 4 moxifloxacin;polytrim
28 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
29 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
30 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
31 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
32 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
33 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
34 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
35 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
36 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
37 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
38 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
39 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
40 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
41 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
42 Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings Completed NCT01433510 Phase 4 Grazax
43 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
44 A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis Completed NCT02256553 Phase 4 Rescue Medication
45 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
46 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
47 The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
48 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
49 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
50 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis Completed NCT01059266 Phase 4 PURETHAL Grasses, 20.000 AUM/ml

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cromolyn
Cromolyn Sodium
Oxymetazoline
Oxymetazoline hydrochloride
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate

Cochrane evidence based reviews: conjunctivitis

Genetic Tests for Conjunctivitis

Genetic tests related to Conjunctivitis:

# Genetic test Affiliating Genes
1 Conjunctivitis 29

Anatomical Context for Conjunctivitis

MalaCards organs/tissues related to Conjunctivitis:

40
Eye, Testes, Skin, T Cells, Heart, Lung, Bone

Publications for Conjunctivitis

Articles related to Conjunctivitis:

(show top 50) (show all 10811)
# Title Authors PMID Year
1
[Lacrimal assessment of lg E in cases with allergic conjunctivitis]. 54 61
20361659 2009
2
Traffic-related outdoor air pollution and respiratory symptoms in children: the impact of adjustment for exposure measurement error. 54 61
18379431 2008
3
IgE antibody on worn highly oxygen-permeable silicone hydrogel contact lenses from patients with contact lens-induced papillary conjunctivitis (CLPC). 54 61
18327049 2008
4
[Tumor necrosis factor receptor associated periodic syndrome (TRAPS). Report of two cases]. 54 61
17277873 2006
5
[Tear eosinophil cationic protein measurement in patients with seasonal allergic conjunctivitis]. 54 61
16491868 2006
6
Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome. 54 61
15245511 2004
7
The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. 54 61
11443543 2001
8
Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis. 54 61
11148813 2000
9
Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. 54 61
10756233 2000
10
Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. 54 61
9856836 1998
11
[Value of lacrymal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis]. 54 61
9759406 1998
12
Eosinophil granule proteins expressed in ocular cicatricial pemphigoid. 54 61
9602632 1998
13
Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure. 54 61
8648032 1996
14
Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. 54 61
8612470 1995
15
Epidemiological Association Between Systemic Diseases and Keratoconus in a Korean Population: A 10-Year Nationwide Cohort Study. 61
31764280 2020
16
Miniaturized turbidimetric assay: A green option for the analysis of besifloxacin in ophthalmic suspension. 61
31892089 2020
17
Eye Socket Regeneration and Reconstruction. 61
31910675 2020
18
Forecast of the trend in incidence of acute hemorrhagic conjunctivitis in China from 2011-2019 using the Seasonal Autoregressive Integrated Moving Average (SARIMA) and Exponential Smoothing (ETS) models. 61
31953020 2020
19
Alopecia Areata is Associated with Atopic Diathesis; Results from a Population-Based Study of 51,561 Patients. 61
32036002 2020
20
Dupilumab Therapy in a Patient with Atopic Dermatitis and Severe Atopic Keratoconjunctivitis. 61
32031716 2020
21
Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records. 61
31286499 2020
22
Comparison of bronchial and nasal allergen provocation in children and adolescents with bronchial asthma and house dust mite sensitization. 61
31660641 2020
23
The KS-Pexy: A Novel Method to Manage Horizontal Lower Eyelid Laxity. 61
31985625 2020
24
Milestones in the fight to eliminate trachoma. 61
32017172 2020
25
Ocular involvement in epidermolysis bullosa acquisita with long-term follow-up. 61
31088794 2020
26
[Staphylococcal scalded skin syndrome in a pediatric patient with atopic dermatitis]. 61
31984705 2020
27
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. 61
31374300 2020
28
Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis. 61
31465590 2020
29
Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors. 61
31761119 2020
30
ICON: Diagnosis and management of allergic conjunctivitis. 61
31759180 2020
31
Ophthalmic manifestations of arbovirus infections in adults. 61
31679764 2020
32
Zika virus: an emerging challenge to public health worldwide. 61
31682478 2020
33
Clinical relevance of Zika symptoms in the context of a Zika Dengue epidemic. 61
31399372 2020
34
High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. 61
32012328 2020
35
Prevalence and Treatment Outcome of Nasolacrimal Duct Obstruction in Saudi Children with Down Syndrome. 61
31976186 2020
36
Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis. 61
32027675 2020
37
SURVEY OF CLINICAL OPHTHALMIC DISEASE IN THE GIANT PANDA (AILUROPODA MELANOLEUCA) AMONG NORTH AMERICAN ZOOLOGICAL INSTITUTIONS. 61
31926513 2020
38
Characterization of Progressive Cicatrizing Conjunctivitis With Negative Immunofluorescence Staining. 61
31560878 2020
39
Ocular surface involvement in pemphigus vulgaris: An interdisciplinary review. 61
31614200 2020
40
Corneal Ulcer Treated with 0.66% Nanoemulsion Povidone-Iodine: A Case Report. 61
31974332 2020
41
Chronic Conjunctivitis From a Retained Contact Lens. 61
30724838 2020
42
Nationwide survey of the prevalence of wheeze, rhino-conjunctivitis, and eczema among Japanese children in 2015. 61
31548125 2020
43
Phenotypic diversity in an emerging mycoplasmal disease. 61
31639466 2020
44
[Chlamydia trachomatis conjunctivitis]. 61
31753423 2020
45
First isolation of human adenovirus type 85 by molecular analysis of adenoviruses in cases of urethritis. 61
31971505 2020
46
An international registry of patients with plasminogen deficiency (HISTORY). 61
32001536 2020
47
Naja atra venom-spit ophthalmia in Taiwan: An epidemiological survey from 1990 to 2016. 61
31714443 2020
48
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. 61
31593343 2020
49
Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. 61
31932274 2020
50
Punctal stenosis associated with dupilumab therapy for atopic dermatitis. 61
31888394 2020

Variations for Conjunctivitis

Expression for Conjunctivitis

Search GEO for disease gene expression data for Conjunctivitis.

Pathways for Conjunctivitis

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 TNF TLR3 RNASE3 NLRP3 NLRC4 IL6
2
Show member pathways
13.88 TNF IL6 IL5 IL4 IL2 IL13
3
Show member pathways
13.79 TNF IL6 IL5 IL4 IL33 IL2
4
Show member pathways
13.66 TNF IL6 IL5 IL4 IL2 IL13
5
Show member pathways
13.53 TNF TLR3 IL6 IL5 IL4 IL2
6
Show member pathways
13.45 TNF IL6 IL5 IL4 IL33 IL2
7
Show member pathways
13.41 TNF IL6 IL5 IL4 IL2 IL13
8
Show member pathways
13.26 TNF TLR3 NLRP3 NLRC4 IL6 IL2
9 12.97 IL6 IL5 IL4 IL2 IL13 IFNG
10
Show member pathways
12.94 TNF TLR3 PLG NLRP3 IL6 IL33
11
Show member pathways
12.87 TNF TLR3 IL6 IL33 IFNG CXCL8
12
Show member pathways
12.76 TNF IL6 IL5 IL4 IL2 IL13
13
Show member pathways
12.75 TNF IL4 IL2 IL10 IGHE IFNG
14
Show member pathways
12.75 TNF IL6 IL5 IL4 IL2 IL10
15
Show member pathways
12.72 TNF PLG IL6 IL2 IL10 IFNG
16 12.72 TNF TLR3 IL4 IL2 IL10 IFNG
17
Show member pathways
12.67 TNF IL5 IL4 IL13 IGHE
18
Show member pathways
12.61 TNF IL4 IL2 IFNG ICAM1
19
Show member pathways
12.52 IL6 IL5 IL4 IL2 IL13 IL10
20
Show member pathways
12.52 TNF IL6 IL5 IL4 IL13 IFNG
21
Show member pathways
12.5 TNF PLG IL6 IL4 IL2 IFNG
22
Show member pathways
12.49 TNF IL6 IL2 IL10 CXCL8 CCL11
23
Show member pathways
12.45 IL4 IGHE HRH1 CCL11
24 12.43 TNF NLRP3 NLRC4 CXCL8
25
Show member pathways
12.43 TNF TLR3 IL6 IFNG CXCL8
26
Show member pathways
12.41 TNF IL6 IL5 IL4 IL2 IL13
27 12.4 TNF IL6 IL2 ICAM1
28 12.37 TNF NLRP3 NLRC4 IL6 CXCL8
29 12.36 TNF NLRP3 IL6 CXCL8
30
Show member pathways
12.35 TNF TLR3 NLRP3 IL33 IFNG
31
Show member pathways
12.35 TNF NLRP3 IL6 IL2 IL10
32
Show member pathways
12.35 TNF IL6 IL4 IFNG CXCL8 CCL11
33
Show member pathways
12.33 TNF TLR3 IL6 CXCL8
34
Show member pathways
12.33 TNF IL4 IL10 IFNG
35 12.31 TNF IL6 IL10 IFNG
36 12.31 TNF IL6 IL13 IL10 CXCL8
37
Show member pathways
12.3 TNF IL6 IL33 CXCL8
38 12.27 TNF TLR3 IL6 IFNG
39
Show member pathways
12.23 TNF TLR3 IL6 IL2 IL10 IFNG
40
Show member pathways
12.22 TNF PLG IL6 IL4 IL13 IFNG
41 12.21 TNF IL6 IL4 IL2 IFNG ICAM1
42 12.19 TNF NLRP3 IL6 IL2 IL10 CXCL8
43 12.18 TNF IL6 IL5 IL4 IL2 IL10
44
Show member pathways
12.18 TNF RNASE3 IL6 IL5 IL4 IL2
45
Show member pathways
12.13 TLR3 IL5 IL2 IL13
46 12.09 TNF IL6 IL10 IFNG CXCL8
47 12.04 TNF IL6 IFNG ICAM1 CXCL8
48 12.03 TNF IL6 ICAM1 CXCL8
49 12.02 TNF IL6 IL5 IL4
50
Show member pathways
11.99 IL6 ICAM1 FOXP3 CXCL8

GO Terms for Conjunctivitis

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 TNF RNASE3 PLG NLRP3 IL6 IL5
2 extracellular space GO:0005615 9.5 TNF TLR3 RNASE3 PLG IL6 IL5

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 TLR3 NLRP3 IL6 IL5 IL4 IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 TNF TLR3 NLRP3 IL6 IL4 IL33
3 positive regulation of transcription, DNA-templated GO:0045893 10.17 TNF IL6 IL5 IL4 IL10 FOXP3
4 negative regulation of cell proliferation GO:0008285 10.13 PLG IL6 IL10 FOXP3 CXCL8
5 defense response to virus GO:0051607 10.02 TLR3 NLRP3 IL6 IL33 IFNG
6 defense response to bacterium GO:0042742 10.01 TNF TLR3 RNASE3 NLRC4 IL10 IGHE
7 defense response GO:0006952 9.99 TNF TLR3 NLRP3 CXCL8
8 negative regulation of inflammatory response GO:0050728 9.98 NLRP3 IL2 IL10 FOXP3
9 positive regulation of gene expression GO:0010628 9.97 TNF TLR3 IL6 IL4 IL33 IL13
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.96 TNF IL6 IL5 IL10
11 defense response to Gram-positive bacterium GO:0050830 9.95 TNF RNASE3 NLRP3 IL6
12 positive regulation of inflammatory response GO:0050729 9.93 TNF TLR3 IL33 IL2
13 response to virus GO:0009615 9.91 TNF TLR3 IFNG FOXP3 CCL11
14 cellular response to lipopolysaccharide GO:0071222 9.91 TNF NLRP3 IL6 IL10 ICAM1 CXCL8
15 response to glucocorticoid GO:0051384 9.9 TNF IL6 IL10
16 positive regulation of interleukin-6 production GO:0032755 9.9 TNF TLR3 IL6 IL33
17 immune response GO:0006955 9.9 TNF IL6 IL5 IL4 IL2 IL13
18 positive regulation of T cell proliferation GO:0042102 9.89 IL6 IL4 IL2
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF IL6 IL13
20 humoral immune response GO:0006959 9.89 TNF IL6 IFNG
21 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF TLR3 NLRP3 NLRC4 IL6 ICAM1
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF IFNG ICAM1
23 negative regulation of interleukin-6 production GO:0032715 9.85 TNF IL10 FOXP3
24 extrinsic apoptotic signaling pathway GO:0097191 9.85 TNF TLR3 IL33 IFNG
25 negative regulation of interferon-gamma production GO:0032689 9.84 IL33 IL10 FOXP3
26 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 CCL11
27 positive regulation of B cell proliferation GO:0030890 9.83 IL5 IL4 IL2 IL13
28 positive regulation of interleukin-4 production GO:0032753 9.8 NLRP3 IL33 FOXP3
29 positive regulation of chemokine production GO:0032722 9.8 TNF TLR3 IL6
30 negative regulation of endothelial cell apoptotic process GO:2000352 9.8 IL4 IL13 IL10 ICAM1
31 positive regulation of macrophage activation GO:0043032 9.79 IL33 IL13 IL10
32 regulation of regulatory T cell differentiation GO:0045589 9.78 IL2 IFNG FOXP3
33 positive regulation of JAK-STAT cascade GO:0046427 9.78 TNF IL6 IL5 IL10
34 positive regulation of neuroinflammatory response GO:0150078 9.77 TNF IL6 IL33
35 positive regulation of chemokine biosynthetic process GO:0045080 9.76 TNF TLR3 IFNG
36 microglial cell activation GO:0001774 9.76 TNF TLR3 IL13 IFNG
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.74 IL4 IL10 IFNG
38 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
39 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IL4 IL2
40 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.73 IL4 IL10
41 negative regulation of lipid storage GO:0010888 9.73 TNF IL6
42 positive regulation of interleukin-13 production GO:0032736 9.73 NLRP3 IL4 IL33
43 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TNF IL6 IL4 IL2 IL13 IFNG
44 negative regulation of T-helper 17 cell differentiation GO:2000320 9.72 IL2 FOXP3
45 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10
46 positive regulation of interleukin-5 production GO:0032754 9.72 NLRP3 IL33
47 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.71 NLRP3 IL6
48 necroptotic signaling pathway GO:0097527 9.71 TNF TLR3
49 negative regulation of lymphocyte proliferation GO:0050672 9.71 IL2 FOXP3
50 positive regulation of type 2 immune response GO:0002830 9.71 NLRP3 IL33

Molecular functions related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 TNF IL6 IL5 IL4 IL33 IL2
2 growth factor activity GO:0008083 9.35 IL6 IL5 IL4 IL2 IL10

Sources for Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....